Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Renews GMP certifications for India and Malaysia sites
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
The company had earlier announced about the approval received from the MHRA for Liraglutide
Subscribe To Our Newsletter & Stay Updated
